Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1975 1
1996 2
1999 1
2006 1
2007 2
2008 2
2009 5
2010 10
2011 5
2012 6
2013 8
2014 4
2015 4
2016 5
2017 3
2018 7
2019 11
2020 15
2021 16
2022 8
2023 6
2024 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

105 results

Results by year

Filters applied: . Clear all
Page 1
GD2-CART01 for Relapsed or Refractory High-Risk Neuroblastoma.
Del Bufalo F, De Angelis B, Caruana I, Del Baldo G, De Ioris MA, Serra A, Mastronuzzi A, Cefalo MG, Pagliara D, Amicucci M, Li Pira G, Leone G, Bertaina V, Sinibaldi M, Di Cecca S, Guercio M, Abbaszadeh Z, Iaffaldano L, Gunetti M, Iacovelli S, Bugianesi R, Macchia S, Algeri M, Merli P, Galaverna F, Abbas R, Garganese MC, Villani MF, Colafati GS, Bonetti F, Rabusin M, Perruccio K, Folsi V, Quintarelli C, Locatelli F; Precision Medicine Team–IRCCS Ospedale Pediatrico Bambino Gesù. Del Bufalo F, et al. Among authors: de angelis b. N Engl J Med. 2023 Apr 6;388(14):1284-1295. doi: 10.1056/NEJMoa2210859. N Engl J Med. 2023. PMID: 37018492
Neutralizing IFNγ improves safety without compromising efficacy of CAR-T cell therapy in B-cell malignancies.
Manni S, Del Bufalo F, Merli P, Silvestris DA, Guercio M, Caruso S, Reddel S, Iaffaldano L, Pezzella M, Di Cecca S, Sinibaldi M, Ottaviani A, Quadraccia MC, Aurigemma M, Sarcinelli A, Ciccone R, Abbaszadeh Z, Ceccarelli M, De Vito R, Lodi MC, Cefalo MG, Mastronuzzi A, De Angelis B, Locatelli F, Quintarelli C. Manni S, et al. Among authors: de angelis b. Nat Commun. 2023 Jun 9;14(1):3423. doi: 10.1038/s41467-023-38723-y. Nat Commun. 2023. PMID: 37296093 Free PMC article.
Allogeneic, donor-derived, second-generation, CD19-directed CAR-T cells for the treatment of pediatric relapsed/refractory BCP-ALL.
Del Bufalo F, Becilli M, Rosignoli C, De Angelis B, Algeri M, Hanssens L, Gunetti M, Iacovelli S, Li Pira G, Girolami E, Leone G, Lazzaro S, Bertaina V, Sinibaldi M, Di Cecca S, Iaffaldano L, Künkele A, Boccieri E, Del Baldo G, Pagliara D, Merli P, Carta R, Quintarelli C, Locatelli F. Del Bufalo F, et al. Among authors: de angelis b. Blood. 2023 Jul 13;142(2):146-157. doi: 10.1182/blood.2023020023. Blood. 2023. PMID: 37172203 Free article.
MYOD-SKP2 axis boosts tumorigenesis in fusion negative rhabdomyosarcoma by preventing differentiation through p57Kip2 targeting.
Pomella S, Cassandri M, D'Archivio L, Porrazzo A, Cossetti C, Phelps D, Perrone C, Pezzella M, Cardinale A, Wachtel M, Aloisi S, Milewski D, Colletti M, Sreenivas P, Walters ZS, Barillari G, Di Giannatale A, Milano GM, De Stefanis C, Alaggio R, Rodriguez-Rodriguez S, Carlesso N, Vakoc CR, Velardi E, Schafer BW, Guccione E, Gatz SA, Wasti A, Yohe M, Ignatius M, Quintarelli C, Shipley J, Miele L, Khan J, Houghton PJ, Marampon F, Gryder BE, De Angelis B, Locatelli F, Rota R. Pomella S, et al. Among authors: de angelis b. Nat Commun. 2023 Dec 15;14(1):8373. doi: 10.1038/s41467-023-44130-0. Nat Commun. 2023. PMID: 38102140 Free PMC article.
Safe and effective off-the-shelf immunotherapy based on CAR.CD123-NK cells for the treatment of acute myeloid leukaemia.
Caruso S, De Angelis B, Del Bufalo F, Ciccone R, Donsante S, Volpe G, Manni S, Guercio M, Pezzella M, Iaffaldano L, Silvestris DA, Sinibaldi M, Di Cecca S, Pitisci A, Velardi E, Merli P, Algeri M, Lodi M, Paganelli V, Serafini M, Riminucci M, Locatelli F, Quintarelli C. Caruso S, et al. Among authors: de angelis b. J Hematol Oncol. 2022 Nov 5;15(1):163. doi: 10.1186/s13045-022-01376-3. J Hematol Oncol. 2022. PMID: 36335396 Free PMC article.
GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma.
Ciccone R, Quintarelli C, Camera A, Pezzella M, Caruso S, Manni S, Ottaviani A, Guercio M, Del Bufalo F, Quadraccia MC, Orlando D, Di Cecca S, Sinibaldi M, Aurigemma M, Iaffaldano L, Sarcinelli A, D'Amore ML, Ceccarelli M, Nazio F, Marabitti V, Giorda E, Pezzullo M, De Stefanis C, Carai A, Rossi S, Alaggio R, Del Baldo G, Becilli M, Mastronuzzi A, De Angelis B, Locatelli F. Ciccone R, et al. Among authors: de angelis b. Clin Cancer Res. 2024 Jun 3;30(11):2545-2557. doi: 10.1158/1078-0432.CCR-23-1880. Clin Cancer Res. 2024. PMID: 38551501 Free PMC article.
Overcoming Challenges in CAR T-cell Product CGMP Release.
Quintarelli C, Locatelli F, Caruana I, De Angelis B. Quintarelli C, et al. Among authors: de angelis b. Mol Ther. 2016 May;24(5):845-6. doi: 10.1038/mt.2016.72. Mol Ther. 2016. PMID: 27198849 Free PMC article. No abstract available.
Challenges in the management of chronic wound infections.
Falcone M, De Angelis B, Pea F, Scalise A, Stefani S, Tasinato R, Zanetti O, Dalla Paola L. Falcone M, et al. Among authors: de angelis b. J Glob Antimicrob Resist. 2021 Sep;26:140-147. doi: 10.1016/j.jgar.2021.05.010. Epub 2021 Jun 16. J Glob Antimicrob Resist. 2021. PMID: 34144200 Free article. Review.
Time to evolve: predicting engineered T cell-associated toxicity with next-generation models.
Donnadieu E, Luu M, Alb M, Anliker B, Arcangeli S, Bonini C, De Angelis B, Choudhary R, Espie D, Galy A, Holland C, Ivics Z, Kantari-Mimoun C, Kersten MJ, Köhl U, Kuhn C, Laugel B, Locatelli F, Marchiq I, Markman J, Moresco MA, Morris E, Negre H, Quintarelli C, Rade M, Reiche K, Renner M, Ruggiero E, Sanges C, Stauss H, Themeli M, Van den Brulle J, Hudecek M, Casucci M. Donnadieu E, et al. Among authors: de angelis b. J Immunother Cancer. 2022 May;10(5):e003486. doi: 10.1136/jitc-2021-003486. J Immunother Cancer. 2022. PMID: 35577500 Free PMC article. Review.
Time 2EVOLVE: predicting efficacy of engineered T-cells - how far is the bench from the bedside?
Guedan S, Luu M, Ammar D, Barbao P, Bonini C, Bousso P, Buchholz CJ, Casucci M, De Angelis B, Donnadieu E, Espie D, Greco B, Groen R, Huppa JB, Kantari-Mimoun C, Laugel B, Mantock M, Markman JL, Morris E, Quintarelli C, Rade M, Reiche K, Rodriguez-Garcia A, Rodriguez-Madoz JR, Ruggiero E, Themeli M, Hudecek M, Marchiq I. Guedan S, et al. Among authors: de angelis b. J Immunother Cancer. 2022 May;10(5):e003487. doi: 10.1136/jitc-2021-003487. J Immunother Cancer. 2022. PMID: 35577501 Free PMC article. Review.
105 results